Compare BRX & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRX | DVA |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.1B |
| IPO Year | 2013 | 2002 |
| Metric | BRX | DVA |
|---|---|---|
| Price | $29.51 | $150.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 4 |
| Target Price | $30.42 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.6M | 738.1K |
| Earning Date | 04-27-2026 | 02-02-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | 1.25 | ★ 9.84 |
| Revenue | $1,371,597,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $5.13 | $3.80 |
| Revenue Next Year | $1.18 | $3.04 |
| P/E Ratio | $23.67 | ★ $15.16 |
| Revenue Growth | ★ 6.73 | 6.46 |
| 52 Week Low | $23.84 | $101.00 |
| 52 Week High | $30.71 | $159.42 |
| Indicator | BRX | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 56.36 |
| Support Level | $29.32 | $146.00 |
| Resistance Level | $30.71 | $150.69 |
| Average True Range (ATR) | 0.49 | 4.50 |
| MACD | -0.19 | -1.60 |
| Stochastic Oscillator | 15.16 | 34.10 |
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.